Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin

ClinicalTrials.gov ID: NCT00119314

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00119314. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Carcinoma Unknown Primary: Treatment With Gemcitabine, Docetaxel and Capecitabine (GTX) an Evaluation and Treatment Study of The Cancer Institute of New Jersey Oncology Group

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Drugs used in chemotherapy, such as gemcitabine, docetaxel, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with docetaxel and capecitabine works in treating patients with cancer of unknown primary origin.

Study identification

NCT ID: NCT00119314
Recruitment status: Withdrawn
Study type: Interventional
Phase: Phase 2
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Enrollment: Not listed

Conditions and interventions

Conditions

Carcinoma of Unknown Primary

Interventions

Drug · Procedure

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 2004 (Type not available)
Primary completion: Jul 2005 (Actual)
Completion: Jul 2005 (Actual)
Last update posted: May 27, 2015

2004 – 2005

United States locations

U.S. sites: 6
U.S. states: 1
U.S. cities: 6

Facility	City	State	ZIP	Site status
Cancer Institute of New Jersey at Hamilton	Hamilton	New Jersey	08690	—
Cancer Center at the Mountainside Hospital	Montclair	New Jersey	07042	—
Carol G. Simon Cancer Center at Morristown Memorial Hospital	Morristown	New Jersey	07962	—
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School	New Brunswick	New Jersey	08903	—
Hematology and Oncology Group	Somerset	New Jersey	08873	—
Overlook Hospital	Summit	New Jersey	07902-0220	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00119314, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 27, 2015 · Synced Nov 14, 2026